JenaValve today announced new clinical findings for its Trilogy TAVR system shared last week at the New York Valves 2026 ...
MedPage Today on MSN
JenaValve TAVR device promising for LVAD-associated aortic regurgitation
Good results reported with emergency-use and compassionate-use cases ...
JenaValve’s Trilogy transcatheter aortic valve replacement device for severe aortic regurgitation (TAVR-AR) treatment has obtained pre-market approval (PMA) from the US Food and Drug Administration ...
Transcatheter aortic valve implantation to treat aortic regurgitation (AR) appears to be a relatively safe and effective option in high-risk patients ineligible for surgery, according to a small ...
WASHINGTON, DC—Further follow-up from the ALIGN-AR trial confirm the safety and continued efficacy of the Trilogy heart valve system (JenaValve) for the treatment of patients with severe, symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results